

Sign up sheet for companies to be studied by Club Biomed Partners

Symbol	Company	Experienced Partner (iff available)	Partner 2	Partner 3 (optional)	Partner 4 (if large company)	Partner 5 (iff expertise needed)
VRTX	Vertex ¹		Rana			
NVS	Novartis ¹					
BMS	Bristol-Myers Squibb ²					
IMCL	Imclone ²	Carlos	Andrea	Mona	Bryan	Enrique
AZN	AstraZeneca ²					
IMNX	Immunex ²					
BGEN	Biogen					
Chir	Chiron					
DNA	Genentech					
LGND	Ligand					
RGEN	Regeneron		Rana			
AMGN	Amgen					
MRK	Merk					
MLNM	Millennium					
SEPR	Sepracor					
IVX	Ivax Corp ³					
PFE	Pfizer					
TEVA	Teva Pharmaceuticals					
PDLI	Protein Design Labs					
AMRI	Albany Medical Research ⁴					
CEPH	Cephalon (5S/PP)	Neil	Laura	Hibiki		

TLRK	Tularik		Ellen	Hyunsil		
IDPH	IDECPharmaceuticals (5 stars)		Constance			
LH	Laboratory Corp of America					
BMET	Biomet					
CEGE	Cell Genesys					
XOMA	XOMA		Constance			
CRGN	CuraGen Corp					
CRXA	Corixa					
MEDX	Medarex		Constance			
SIAL	Sigma Aldrich					
STJ	St Jude Medical					
Path	Ameripath (5S/SC/PP/Plat)					
GLGC	Gene Logic INC (SC)					
GENZ	GENZYME (SC)					
Clusters/interest groups						
	Angiogenesis	Enrique	Francesca	Abner		
	Big Pharma Big cap with profits		Garrett	Stephen	Johanna	Gianina
	Antibodies for Cancer	Imke	Karen			
	Big Biotec i.e., big cap, small revenue	Mark	Omar	Earl	Sue	Dasha
	Generic Drugs	Simne	Juliana	Dierdre		
	Small Cap biotechs	Joel	Omar			

5S= five star; SC=small cap; PP=PowerPick; Plat=Platinum
 1,2 JAW's picks (suggested in E-mail with rationale)

¹ I think it would be fun to get a group (2 or 3 Partners) to study Vertex (VRTX) and another cooperating group (3 or 4 Partners) to study Novartis (NVS). Here is the reason:

Vertex is a Biotech that has some products in the marketplace and promises for others. It makes money from selling these products and from research contracts. It has protease inhibitors for AIDS therapy and others. It has followed the idea that rational drug design based on structural studies is the way to go. The early history of the company is outlined in a great book called The Billion Dollar Molecule.

Novartis is a big company with what is said to be a strong and diverse pipeline. Shares have appreciated recently. They recently announced plans to move their main research center to Boston (they will drop \$250 million to build it) and some have speculated this is to be closer to Vertex with whom they have a strong and expensive interaction.

² It would be fun to follow Bristol-Myers Squibb (BMS) and Imclone (IMCL). BMY is a large diversified Drug company that recently sold several businesses to concentrate on drug development. They bought a joint venture between Merck and DuPont to fill out their research pipeline. Some say they bought a good resource, but paid too much. Their stock has been falling lately for several reasons, with both good and bad news about their products. The main reason I would like to study them is their interaction with Imclone. They paid 2 Billion Dollars (that's right Billion) for the rights to a drug called Erbitux, which is an anti EGFR antibody. This type of antibody has promise in several types of tumors, but both companies got killed when the FDA refused to review the drug because of inadequacies of the clinical trials. Andrea has expressed interest in studying Imclone and

Carlos would be interested in working with her. If we could get a few more to work with them and concentrate on BMS that should make an interesting story. We might even be able to put together a preliminary report by the July meeting. Since there are several other companies developing anti EGFR antibodies, it might be interesting if we could get a group studying one of these companies so we can contrast it with IMCL. I think Immunex (IMNX) is developing an antibody and AstraZeneca (AZN) is developing a small molecule inhibitor of the EGF receptor (ZD1839 (IRESSA(R))). If we have enough interest in this area, it would be fun to compare the different companies,

3. IVAX has a P/E of 10!

4. AMRI has a P/E of 24!

Constance Hsia at 2:05pm:Some other companies to consider perhaps already on the list: Corixa

(CRXA), Medarex (MEDX), IDEC (IDEC), XOMA(XOMA)

Derek suggested tul and curagen

CRXA	Corixa
MEDX	Medarex
IDEC	IDEC
XOMA	XOMA
CRGN	CuraGen Corp

Gene Marcial, who writes a column for Business Week produced an essay strongly supporting the prospects of Cell Genesys (CEGE). I think I will add it to the list of stocks that would be good companies to look at. You can

find his essay at:

http://biz.yahoo.com/bizwk/020612/nf200206115102_1.html